CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for CytomX Therapeutics stock has a target of 2.50, which predicts an increase of 17.37% from the current stock price of 2.13.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.50	$2.50	$2.50	$2.50
Change	+17.37%	+17.37%	+17.37%	+17.37%

Analyst Ratings

The average analyst rating for CytomX Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25	May '25
Strong Buy	1	1	1	1	1	0
Buy	2	2	2	2	2	1
Hold	3	3	3	3	3	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Catanzaro Piper Sandler	Piper Sandler	Buy Maintains $3.25 → $2.5	Buy	Maintains	$3.25 → $2.5	+17.37%	Apr 14, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Mar 7, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Jan 7, 2025
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Nov 11, 2024
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Sep 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

101.22M

Decreased by -26.71%

from 138.10M

Revenue Next Year

29.82M

Decreased by -70.54%

from 101.22M

EPS This Year

0.01

Decreased by -97.64%

from 0.38

EPS Next Year

-0.61

from 0.01

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	68.43M	37.31M	53.16M	101.21M	138.10M	101.22M	29.82M	18.19M
Revenue Growth	154.36%	-45.47%	42.48%	90.38%	36.45%	-26.71%	-70.54%	-39.00%
EPS	-1.40	-1.81	-1.51	-0.01	0.38	0.01	-0.61	-0.65
EPS Growth	-	-	-	-	-	-97.64%	-	-
Forward PE	-	-	-	-	-	238.66	-	-
No. Analysts	-	-	-	-	-	8	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	163.3M	107.1M	52.5M
Avg	101.2M	29.8M	18.2M
Low	49.0M	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	18.2%	5.8%	76.0%
Avg	-26.7%	-70.5%	-39.0%
Low	-64.5%	-	-

EPS Forecast

EPS	2025	2026	2027	2028
High	0.29	0.15	-0.53
Avg	0.01	-0.61	-0.65
Low	-0.43	-0.99	-0.83

EPS Growth

EPS Growth	2025	2026	2027	2028
High	-23.5%	1,547.1%	-
Avg	-97.6%	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.